Is Pfizer a Buy, Sell, or Hold in 2026?

A few years ago, Pfizer (NYSE: PFE) looked unstoppable. The company generated more than $100 billion in annual revenue early in the pandemic, powered by its COVID-19 vaccine and antiviral treatment. Investors piled into the stock, expecting the pharmaceutical giant to convert its pandemic windfall into a new era of long-term growth.That didn't happen. COVID revenue collapsed. The stock fell more than 60% from its pandemic highs. Now, let's reevaluate the question: Is Pfizer a buy, sell, or hold?Pfizer stock currently trades at less than 9 times forward earnings while yielding more than 6%, making it one of the cheapest large-cap pharmaceutical stocks on the market. That immediately gets income investors interested. But low valuations alone don't make a stock a buy.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool